KalVista Pharmaceuticals, Inc. — fact timeline

KalVista Pharmaceuticals, Inc.: Amended and restated bylaws in full.

“as of the Effective Time, the Company’s bylaws, as in effect immediately prior to the Effective Time, were amended and restated in full”

KalVista Pharmaceuticals, Inc.: Amended and restated certificate of incorporation in its entirety.

“As of the Effective Time, the Company’s certificate of incorporation, as in effect immediately prior to the Effective Time, was amended and restated in its entirety”

KalVista Pharmaceuticals, Inc. underwent a change of control involving Chiesi Farmaceutici S.p.A. for $27.00 per Share in cash (closed 2026-06-11).

“Purchaser commenced a tender offer (the “ Offer ”) to acquire all of the outstanding shares of common stock of the Company, par value $0.001 per share (the “ Shares ”), for $27.00 per Share, net to the seller in cash, without interest and subject to any withholding of taxes (the “ Offer Price ”). The Offer and withdrawal rights expired at one minute”

KalVista Pharmaceuticals, Inc. terminated Company 2017 Employee Stock Purchase Plan with KalVista Pharmaceuticals, Inc. valued at Terminated the Company 2017 Employee Stock Purchase Plan (effective 2026-06-11).

“In addition, and also effective immediately prior to, and contingent upon, the Effective Time, the Company terminated the Company 2017 Employee Stock Purchase Plan.”

KalVista Pharmaceuticals, Inc. terminated Company 2015 Incentive Plan with KalVista Pharmaceuticals, Inc. valued at Terminated the Company 2015 Incentive Plan, the Company 2017 Equity Incentive Plan, and the Company (effective 2026-06-11).

“In connection with the consummation of the Offer and the Merger and effective as of, and contingent upon, the Effective Time, the Company terminated the Company 2015 Incentive Plan, the Company 2017 Equity Incentive Plan, and the Company 2021 Equity Inducement Plan.”

John Hess was appointed as other_named_officer at KalVista Pharmaceuticals, Inc..

“John Hess, President and Secretary of Purchaser, became an officer of the Company.”

John Hess was appointed as Sole Director at KalVista Pharmaceuticals, Inc..

“John Hess, the sole director of Purchaser immediately prior to the Effective Time, became the sole director of the Company”

Edward W. Unkart resigned as Director at KalVista Pharmaceuticals, Inc..

“each of Brian J. G. Pereira, MD, Benjamin L. Palleiko, William Fairey, Laurence Reid, PhD, Bethany Sensenig, Nancy Stuart, Patrick Treanor and Edward W. Unkart resigned from his or her respective positions as a member of the Company’s board of directors”

Patrick Treanor resigned as Director at KalVista Pharmaceuticals, Inc..

“each of Brian J. G. Pereira, MD, Benjamin L. Palleiko, William Fairey, Laurence Reid, PhD, Bethany Sensenig, Nancy Stuart, Patrick Treanor and Edward W. Unkart resigned from his or her respective positions as a member of the Company’s board of directors”

Nancy Stuart resigned as Director at KalVista Pharmaceuticals, Inc..

“each of Brian J. G. Pereira, MD, Benjamin L. Palleiko, William Fairey, Laurence Reid, PhD, Bethany Sensenig, Nancy Stuart, Patrick Treanor and Edward W. Unkart resigned from his or her respective positions as a member of the Company’s board of directors”

Bethany Sensenig resigned as Director at KalVista Pharmaceuticals, Inc..

“each of Brian J. G. Pereira, MD, Benjamin L. Palleiko, William Fairey, Laurence Reid, PhD, Bethany Sensenig, Nancy Stuart, Patrick Treanor and Edward W. Unkart resigned from his or her respective positions as a member of the Company’s board of directors”

Laurence Reid, PhD resigned as Director at KalVista Pharmaceuticals, Inc..

“each of Brian J. G. Pereira, MD, Benjamin L. Palleiko, William Fairey, Laurence Reid, PhD, Bethany Sensenig, Nancy Stuart, Patrick Treanor and Edward W. Unkart resigned from his or her respective positions as a member of the Company’s board of directors”

William Fairey resigned as Director at KalVista Pharmaceuticals, Inc..

“each of Brian J. G. Pereira, MD, Benjamin L. Palleiko, William Fairey, Laurence Reid, PhD, Bethany Sensenig, Nancy Stuart, Patrick Treanor and Edward W. Unkart resigned from his or her respective positions as a member of the Company’s board of directors”

Benjamin L. Palleiko resigned as Director at KalVista Pharmaceuticals, Inc..

“each of Brian J. G. Pereira, MD, Benjamin L. Palleiko, William Fairey, Laurence Reid, PhD, Bethany Sensenig, Nancy Stuart, Patrick Treanor and Edward W. Unkart resigned from his or her respective positions as a member of the Company’s board of directors”

Brian J. G. Pereira, MD resigned as Director at KalVista Pharmaceuticals, Inc..

“each of Brian J. G. Pereira, MD, Benjamin L. Palleiko, William Fairey, Laurence Reid, PhD, Bethany Sensenig, Nancy Stuart, Patrick Treanor and Edward W. Unkart resigned from his or her respective positions as a member of the Company’s board of directors”

KalVista Pharmaceuticals, Inc. entered into Agreement and Plan of Merger with Chiesi Farmaceutici S.p.A. valued at $27.00 per Share (effective 2026-04-29).

“On April 29, 2026, KalVista Pharmaceuticals, Inc., a Delaware corporation (the " Company "), entered into an Agreement and Plan of Merger (the " Merger Agreement "), by and among the Company, Chiesi Farmaceutici S.p.A., an Italian società per azioni (" Parent "), Skyline Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (" Purchaser "), and KalVista Pharmaceuticals Limited, a private limited company organized under the laws of England and Wales.”

KalVista Pharmaceuticals, Inc. reported the eight months ended December 31, 2025 results: revenue $49.1 million global net product revenue.

“KalVista Pharmaceuticals Reports Eight Months Fiscal Year 2025 Financial Results and Provides Corporate Update $49.1 million global net product revenue of EKTERLY ® (sebetralstat) for the eight months ended December 31, 2025”

KalVista Pharmaceuticals, Inc. incurred convertible notes of $143.75 million in aggregate principal amount with Initial Purchasers at 3.250% maturing due 2031.

“On September 29, 2025, KalVista Pharmaceuticals, Inc. (the “Company”) completed its previously announced sale of $143.75 million in aggregate principal amount of its 3.250% Convertible Senior Notes due 2031”

Jebediah T. Ledell resigned as Chief Operating Officer at KalVista Pharmaceuticals, Inc..

“On May 12, 2025, Jebediah T. Ledell notified KalVista Pharmaceuticals, Inc. (the “Company”) of his decision to resign from his position as Chief Operating Officer of the Company, effective immediately.”

KalVista Pharmaceuticals, Inc.: The Company changed its fiscal year-end from April 30 to December 31 (effective 2025-03-13).

“On March 13, 2025, the Board of Directors of KalVista Pharmaceuticals, Inc. (the “Company”) approved a change in the Company’s fiscal year-end from April 30 to December 31.”

Brian Piekos was appointed as Chief Financial Officer at KalVista Pharmaceuticals, Inc..

“Effective September 9, 2024, the Board of Directors (the “Board”) of KalVista Pharmaceuticals, Inc. (the “Company”) appointed Brian Piekos as the Company’s Chief Financial Officer, principal financial officer and principal accounting officer.”

William Fairey was appointed as Class III Director at KalVista Pharmaceuticals, Inc..

“the Board approved the appointment of William Fairey (“ Mr. Fairey ”) to the Board effective immediately, to serve until his successor is duly elected and qualified”

KalVista Pharmaceuticals, Inc. reported the fiscal quarter ended January 31, 2024 results: net income $29.0 million, EPS $(0.84) per weighted average basic and diluted share.

“Net loss was $29.0 million, or $(0.84) per weighted average basic and diluted share, for the three months ended January 31, 2024”

Benjamin L. Palleiko was appointed as Chief Executive Officer at KalVista Pharmaceuticals, Inc..

“Effective March 6, 2023, the Board of Directors (the “ Board ”) of KalVista Pharmaceuticals, Inc. (the “ Company ”) appointed Benjamin L. Palleiko, the Company’s President, Chief Business Officer and Chief Financial Officer, as its Chief Executive Officer and principal executive officer and he will remain the principal financial officer.”

T. Andrew Crockett resigned as Chief Executive Officer at KalVista Pharmaceuticals, Inc..

“On March 6, 2024, T. Andrew Crockett announced his resignation from his position as the Chief Executive Officer and from his position on the Board, effective immediately.”

KalVista Pharmaceuticals, Inc. entered into Underwriting Agreement with Jefferies LLC, Leerink Partners LLC, Stifel, Nicolaus & Company, Incorporated, and Cantor Fitzgerald & Co. valued at approximately $150.1 million (effective 2024-02-14).

“On February 14, 2024, KalVista Pharmaceuticals, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, Leerink Partners LLC, Stifel, Nicolaus & Company, Incorporated, and Cantor Fitzgerald & Co., as the representatives of the several underwriters named in Schedule A thereto (the “Underwriters”), pursuant to which the Company agreed to issue and sell (i) an aggregate of 7,016,312 shares of its common stock (the “Shares”) and (ii) pre-funded warrants to purchase 3,483,688 shares of the Company’s common stock in lieu of its common stock (the “Pre-Funded Warrants”) to certain investors, to the Underwriters (the “Offering”).”

KalVista Pharmaceuticals, Inc. terminated Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co. valued at no shares sold under the agreement; aggregate offering price up to $100.0 million (effective 2024-02-14).

“On February 14, 2024, KalVista Pharmaceuticals, Inc. (the “Company”) delivered a written notice of termination (the “Termination Notice”) of that certain Controlled Equity Offering Sales Agreement (the “Sales Agreement”), dated May 21, 2021, by and between the Company and Cantor Fitzgerald & Co., as sales agent (“Cantor”).”

KalVista Pharmaceuticals, Inc. reported the three months ended October 31, 2023 results: revenue No revenue was recognized, net income Net loss was $27.7 million, EPS $(0.80) per weighted average basic and diluted share.

“On December 7, 2023, KalVista Pharmaceuticals, Inc. (the “Company”) reported its financial results for the fiscal quarter ended October 31, 2023.”

KalVista Pharmaceuticals, Inc.: Certificate of amendment to certificate of incorporation to permit exculpation of certain officers from liability in specific circumstances (effective 2023-09-26).

“the Company’s stockholders approved a certificate of amendment (the “Certificate of Amendment”) to the Company’s certificate of incorporation to permit the exculpation of certain of the Company’s officers from liability in specific circumstances.”

KalVista Pharmaceuticals, Inc. shareholders approved Approval of the Certificate of Amendment to limit the liability of certain officers of the company as permitted pursuant to recent amendments to the Delaware General Corporation Law at the 2023-09-26 meeting.

“4. Approval of the Certificate of Amendment to limit the liability of certain officers of the company as permitted pursuant to recent amendments to the Delaware General Corporation Law: Shares For Shares Against Shares Abstaining Broker Non-Votes 20,203,486 2,450,421 1,385 8,184,921”

KalVista Pharmaceuticals, Inc. shareholders approved Approval, on a non-binding advisory basis, of the compensation paid by the Company to its named executive officers at the 2023-09-26 meeting.

“3. Approval, on a non-binding advisory basis, of the compensation paid by the Company to its named executive officers: Shares For Shares Against Shares Abstaining Broker Non-Votes 20,001,348 2,652,134 1,810 8,184,921”

KalVista Pharmaceuticals, Inc. shareholders approved Ratification of the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending April 30, 2024 at the 2023-09-26 meeting.

“2. Ratification of the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending April 30, 2024: Shares For Shares Against Shares Abstaining Broker Non-Votes 30,837,741 1,624 848 N/A”

KalVista Pharmaceuticals, Inc. shareholders approved Election of two Class II directors at the 2023-09-26 meeting.

“On September 26, 2023, the Company held its 2023 Annual Meeting of Stockholders (“ Annual Meeting ”) and the following proposals were adopted: 1. Election of two Class II directors, Patrick Treanor and Edward W. Unkart (each to serve a three-year term, which will expire at the 2026 Annual Meeting of Stockholders or until such time as their respective successors have been duly elected and qualified): Nominees Shares For Shares Against Shares Abstaining Broker Non-Votes Patrick Treanor 15,931,760 6,722,475 1,058 8,184,920 Edward W. Unkart 15,154,122 7,499,378 1,791 8,184,922”

KalVista Pharmaceuticals, Inc. reported the first fiscal quarter ended July 31, 2023 results: net income $25.3 million, or $(0.74) per weighted average basic and diluted share, EPS $(0.74) per weighted average basic and diluted share.

“KalVista Pharmaceuticals Reports First Fiscal Quarter Results and Provides Operational Update”

KalVista Pharmaceuticals, Inc. reported three months ended April 30, 2023 results: revenue No revenue was recognized, net income $26.3 million, EPS $(0.77) per weighted average basic and diluted share.

“Net loss was $26.3 million, or $(0.77) per weighted average basic and diluted share, for the three months ended April 30, 2023”

KalVista Pharmaceuticals, Inc. reported fiscal year ended April 30, 2023 results: revenue No revenue was recognized, net income $92.9 million, EPS $(3.33) per weighted average basic and diluted share.

“Net loss was $92.9 million, or $(3.33) per weighted average basic and diluted share for the fiscal year ended April 30, 2023”

KalVista Pharmaceuticals, Inc.: Adopted amended and restated bylaws effective June 14, 2023, incorporating changes related to universal proxy rules, recent DGCL amendments, and other governance updates (effective 2023-06-14).

“On June 14, 2023, in connection with the effectiveness of new Securities and Exchange Commission rules regarding universal proxy cards, certain recent changes to the Delaware General Corporation Law (the “ DGCL ”), and a periodic review of the bylaws of KalVista Pharmaceuticals, Inc. (the “ Company ”), the Company’s board of directors (the “ Board ”) approved and adopted the Company’s amended and restated bylaws (the “ Amended and Restated Bylaws ”), which became immediately effective.”

Benjamin L. Palleiko was appointed as President at KalVista Pharmaceuticals, Inc..

“On January 4, 2023, KalVista Pharmaceuticals, Inc. (the “Company”) announced the appointment of Benjamin L. Palleiko, currently the Company’s Chief Business Officer and Chief Financial Officer, to the position of President of the Company, effective as of January 4, 2023.”

KalVista Pharmaceuticals, Inc. entered into Subscription Agreements with certain purchasers valued at approximately $58 million (effective 2022-12-23).

“On December 23, 2022, KalVista Pharmaceuticals, Inc. (the “Company”) entered into a subscription agreement (collectively, the “Subscription Agreements”) with certain purchasers, pursuant to which the Company agreed to issue and sell in a registered direct offering (the “Offering”) (i) an aggregate of 9,484,199 shares (the “Shares”) of the Company’s common stock, $0.001 par value per share (“Common Stock”) and (ii) pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 182,470 shares of Common Stock.”

KalVista Pharmaceuticals, Inc. reported second fiscal quarter ended October 31, 2022 results: net income $22.3 million, EPS $(0.90) per weighted average basic and diluted share.

“Net loss was $22.3 million, or $(0.90) per weighted average basic and diluted share, for the three months ended October 31, 2022”

Brian J. G. Pereira was appointed as Chairman of the Board at KalVista Pharmaceuticals, Inc..

“The Board approved the appointment of Brian J. G. Pereira, M.D., as Chairman of the Board, effective upon Dr. Edwards’ resignation.”

Martin Edwards resigned as Chairman of the Board at KalVista Pharmaceuticals, Inc..

“On October 13, 2022, Martin Edwards, M.D., announced his resignation from his position as the Chairman of the Board of Directors (the “Board”) and as a Class III director, member of the Compensation Committee of the Board (the “Compensation Committee”) and member of the Nominating and Corporate Governance Committee of the Board (the “Nominating and Corporate Governance Committee”) of KalVista Pharmaceuticals, Inc. (the “Company”), effective immediately.”

Patrick Treanor was appointed as Director at KalVista Pharmaceuticals, Inc..

“On May 26, 2022 upon the recommendation of the Nominating and Governance Committee of the Board, the Board approved the appointment of Patrick Treanor (“ Mr. Treanor ”) to the Board effective immediately, to serve until his successor is duly elected and qualified, or until his death, resignation or removal.”

Daniel Soland resigned as Director at KalVista Pharmaceuticals, Inc..

“Effective as of May 25, 2022, Daniel Soland resigned from his position on the Board of Directors (the “ Board ”) of KalVista Pharmaceuticals, Inc. (the “ Company ”) and all committees thereof.”